Is the Haleon share price cheap under £3 ahead of earnings?

Research firms are favouring the Haleon share price. Is it time for me to snap some up before its next earnings report?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Nearing the close of its thirteenth trading week, the Haleon (LSE:HLN) share price has had a tough start. Haleon first began trading at 330p and saw lows of almost 240p by the start of September. But since then, it has confidently recovered.

On Tuesday, Haleon was a top FTSE 100 performer with high volumes traded. As I write, the share price stands at 273p.

So, what does Haleon do? Where has the company sprung from? And should I be looking to invest in it?

A FTSE 100 giant subsidiary

Haleon was born out of GSK, a pharmaceutical giant, as its own independent company. It has taken ownership of some big-name brands such as Aquafresh, Panadol, Voltaren, and Nicorette.

The company is a dominant player in supplying oral health, pain relief and vitamin products.

The American pharmaceutical giant Pfizer owns a 25% stake in the new company.

The separation follows as GSK plans to focus its investment efforts on vaccines and speciality medicines. By contrast, Haleon — with a fresh balance sheet — will be a cash-generative business with quality brand names intended to attract investors looking for sustainable growth.

The latest earnings report

During the first week of trading, claims against GSK that one of its drugs, Zantac, causes cancer applied downward pressure to the Haleon share price.

Soon after listing, Haleon increased its expectations for revenue growth. It claims its brands have relatively inelastic demand even when faced with economic uncertainty.

Market commentators speculated otherwise, expecting that consumers would be downgrading to supermarket own-brand products. However, September earnings met expectations with no downside surprise.

This has acted as a springboard for the share price, which has stabilised at 5% higher since the earnings report.

Should I invest?

Meeting its initial growth targets is growing confidence among investors in the new corporate entity and its strategy.

Encouragingly, the company’s e-commerce sales are growing fast and have climbed to 9% of all revenue generation. Analysts are forecasting a 6.8% in annual revenue growth in the medium term.

Over 10 research firms have assigned Haleon a rating of “hold” as their recommendation.

Haleon’s balance sheet currently has relatively low levels of debt in comparison to GSK. Its rich cash flow also gives it plenty of opportunity to manage the debt going forward. This is certainly something I like to see in the face of rising interest rates.

Haleon’s strong portfolio of brands is already holding up against economic decline. With the company newly established, I certainly think there’s an opportunity for the share price to reach new highs as investors chase defensive stocks.

However, the UK recently reported a 0.3% economic contraction. The extent to which contraction continues nationally and internationally may begin to have a more noticeable influence over consumers substituting brands.

There is also a question about GSK’s potential legal liabilities due to its sale of Zantac. Trials will begin next year. Haleon is also at risk to liability but claims otherwise as it has never marketed Zantac. Either way, the outcome of the dispute is likely to have a big impact on the price for both companies.

I plan to buy shares in Haleon should the price fall below 270p again, with the hope that the earnings report on 10 November will be just as solid as the last.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dan Coates has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK plc and Haleon plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »